Estimating impossible curves using NONMEM

被引:83
作者
Schoemaker, RC
Cohen, AF
机构
[1] Centre for Human Drug Research, Leiden
[2] Centre for Human Drug Research, 2333CL Leiden
关键词
parameter estimation; NONMEM; rising dose design; low molecular; weight heparin; POPULATION PHARMACOKINETICS;
D O I
10.1046/j.1365-2125.1996.04231.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 On fitting model equations to experimental data, the situation may arise that individual subjects provide insufficient information to obtain adequate parameter estimates due to the fact that not all aspects are exhibited by all subjects or that the models are simply too complex. This may be solved by applying nonlinear mixed effect modelling to the data, which integrates the information provided by different subjects. 2 We aim to provide insight into the methodology and its use in these situations, illustrated by three examples: determination of pharmacokinetics in a rising dose design, where the lower doses provide insufficient information (due to assay limitations) to estimate terminal half-life; determination of the kinetics of the low molecular weight heparin enoxaparine (ClexaneR) using anti-xa activity, effectively dealing with lingering low/basal activity; simultaneous estimation of the pharmacokinetics and pharmacodynamics of the low molecular weight heparin dalteparine (FragminR) after subcutaneous and intravenous administration.
引用
收藏
页码:283 / 290
页数:8
相关论文
共 11 条
[1]   POPULATION PHARMACOKINETICS OF TOBRAMYCIN [J].
AARONS, L ;
VOZEH, S ;
WENK, M ;
WEISS, P ;
FOLLATH, F .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 28 (03) :305-314
[2]  
[Anonymous], 1992, NONMEM Users Guides
[3]  
DANHOF M, 1994, 2 INT S MEAS KIN VIV
[4]   ESTIMATION OF GENTAMICIN CLEARANCE AND VOLUME OF DISTRIBUTION IN NEONATES AND YOUNG-CHILDREN [J].
KELMAN, AW ;
THOMSON, AH ;
WHITING, B ;
BRYSON, SM ;
STEEDMAN, DA ;
MAWER, GE ;
SAMBADONGA, LA .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1984, 18 (05) :685-692
[5]  
KROON C, 1993, BR J CLIN PHARM, V35, pP548
[6]   NONLINEAR MIXED EFFECTS MODELS FOR REPEATED MEASURES DATA [J].
LINDSTROM, MJ ;
BATES, DM .
BIOMETRICS, 1990, 46 (03) :673-687
[7]   OPPORTUNITIES FOR INTEGRATION OF PHARMACOKINETICS, PHARMACODYNAMICS, AND TOXICOKINETICS IN RATIONAL DRUG DEVELOPMENT [J].
PECK, CC ;
BARR, WH ;
BENET, LZ ;
COLLINS, J ;
DESJARDINS, RE ;
FURST, DE ;
HARTER, JG ;
LEVY, G ;
LUDDEN, T ;
RODMAN, JH ;
SANATHANAN, L ;
SCHENTAG, JJ ;
SHAH, VP ;
SHEINER, LB ;
SKELLY, JP ;
STANSKI, DR ;
TEMPLE, RJ ;
VISWANATHAN, CT ;
WEISSINGER, J ;
YACOBI, A .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (04) :465-473
[8]   POPULATION PHARMACOKINETICS DYNAMICS [J].
SHEINER, LB ;
LUDDEN, TM .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1992, 32 :185-209
[9]   A CROSS-OVER COMPARISON OF THE ANTI-CLOTTING EFFECTS OF 3 LOW-MOLECULAR-WEIGHT HEPARINS AND GLYCOSAMINOGLYCURONAN [J].
STIEKEMA, JCJ ;
VANGRIENSVEN, JMT ;
VANDINTHER, TG ;
COHEN, AF .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 36 (01) :51-56
[10]  
VANBOXTEL CJ, 1992, IN VIVO STUDY DRUG A